Patients must not be known to be refractory to red blood cell or platelet transfusionsXx_NEWLINE_xXPatients with known bone marrow metastatic disease will be eligible for study provided they meet the blood counts above (may receive transfusions provided they are not known to be refractory to red cell or platelet transfusions); these patients will not be evaluable for hematologic toxicity; at least 5 of every cohort of 6 patients with a solid tumor must be evaluable for hematologic toxicity, for Parts A and C; if dose-limiting hematologic toxicity is observed on either Part A or C, all subsequent patients enrolled must be evaluable for hematologic toxicity on that PartXx_NEWLINE_xXHemoglobin >= 10.0 g/dL and no blood transfusions in the 28 days prior to entry/randomizationXx_NEWLINE_xXFor patients with solid tumors without known bone marrow involvement:\r\n* Peripheral absolute neutrophil count (ANC) >= 1000/mm^3\r\n* Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)\r\n* Hemoglobin >= 8.0 g/dl at baseline (may receive red blood cell [RBC] transfusions)Xx_NEWLINE_xXPatients with known bone marrow metastatic disease will be eligible for the study if they meet the following criteria: \r\n* Peripheral absolute neutrophil count (ANC) >= 750/mm^3\r\n* Platelet count >= 50,000/mm^3 (may receive transfusions provided they are not known to be refractory to red cell or platelet transfusions)\r\n* Hemoglobin >= 8.0 g/dL at baseline (may receive red blood cell [RBC] transfusions, provided they are not known to be refractory to RBC transfusions); these patients will not be evaluable for hematologic toxicity; at least 5 of every cohort of 6 patients must be evaluable for hematologic toxicity for the dose-escalation part of the study; if dose-limiting hematologic toxicity is observed, all subsequent patients enrolled must be evaluable for hematologic toxicityXx_NEWLINE_xXFor patients with solid tumors without known bone marrow involvement: \r\n* Peripheral absolute neutrophil count (ANC) >= 1000/mm^3\r\n* Platelet count >= 75,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)\r\n* Hemoglobin >= 8.0 g/dl at baseline (may receive packed red blood cell [PRBC] transfusions)Xx_NEWLINE_xXPatients with known bone marrow metastatic disease will be eligible for study provided they meet the blood counts (may receive transfusions provided they are not known to be refractory to red cell or platelet transfusions); these patients will not be evaluable for hematologic toxicity; at least 5 of every cohort of 6 patients must be evaluable for hematologic toxicity for the dose-escalation part of the study; if dose-limiting hematologic toxicity is observed, all subsequent patients enrolled must be evaluable for hematologic toxicityXx_NEWLINE_xXHemoglobin ? 10 g/dL with no blood transfusions (packed red blood cells and platelet transfusions) in the past 28 days, within 28 days prior to administration of study treatmentXx_NEWLINE_xXWhole blood transfusions in the last 120 days prior to entry to the study (packed red blood cells and platelet transfusions are acceptableXx_NEWLINE_xX* Hemoglobin >= 8.0 g/dL at baseline (may receive red blood cell [RBC] transfusions)Xx_NEWLINE_xXPatients with known bone marrow metastatic disease will be eligible for study if they meet the blood counts (may receive transfusions provided they are not known to be refractory to red cell or platelet transfusions); these patients will not be evaluable for hematologic toxicity; at least 5 of every cohort of 6 patients must be evaluable for hematologic toxicity for the dose-escalation part of the study; if dose-limiting hematologic toxicity is observed, all subsequent patients enrolled on Part A must be evaluable for hematologic toxicityXx_NEWLINE_xXFor patients with solid tumors without known bone marrow involvement: hemoglobin >= 8.0 g/dL (may receive red blood cell [RBC] transfusions)Xx_NEWLINE_xXPatients with known bone marrow metastatic disease will be eligible for study provided they meet the blood counts (may receive transfusions provided they are not known to be refractory to red cell or platelet transfusions); these patients will not be evaluable for hematologic toxicity; at least 2 of every cohort of 3 patients must be evaluable for hematologic toxicity for Part A, the dose escalation part of the study; if dose-limiting hematologic toxicity is observed, all subsequent patients enrolled must be evaluable for hematologic toxicityXx_NEWLINE_xXPatients with known bone marrow metastatic disease will be eligible for study provided they meet the blood counts (may receive transfusions provided they are not known to be refractory to red cell or platelet transfusions); these patients will not be evaluable for hematologic toxicity; at least 5 of every cohort of 6 patients on Part A1 must be evaluable for hematologic toxicity for the dose-escalation part of the study; if dose-limiting hematologic toxicity is observed, all subsequent patients enrolled must be evaluable for hematologic toxicityXx_NEWLINE_xXPatients must not have had hemoptysis of >= 0.5 teaspoon (2.5 ml) of red blood within 3 months prior registrationXx_NEWLINE_xXWhole blood transfusions in the last 120 days prior to entry to the study which may interfere with gBRCA testing (packed red blood cells and platelet transfusions are acceptable)Xx_NEWLINE_xXHemoglobin >= 8 g/dL for patients =< 16 years of age; >= 9 g/dL for patients > 16 years of age; Note: no transfusions are permitted 7 days prior to laboratory studies to determine eligibilityXx_NEWLINE_xXNo platelet transfusions within 7 days of registration to meet eligibility criteria; Note: red blood cell transfusions are allowed at any timeXx_NEWLINE_xXHemoglobin >= 10.0 g/dL (may receive red blood cell [RBC] transfusions)Xx_NEWLINE_xXHemoglobin >= 8.0 g/dL (may receive red blood cell [RBC] transfusions) for patients with solid tumors without bone marrow involvementXx_NEWLINE_xXTransfusions are permitted to meet both the platelet and hemoglobin criteria; patients must not be known to be refractory to red blood cell or platelet transfusionsXx_NEWLINE_xXPatients with known bone marrow metastatic disease will be eligible for study provided they meet the blood counts in (may receive platelet or packed red blood cells [pRBC] transfusions provided they are not known to be refractory to red cell or platelet transfusions); these patients will not be evaluable for hematologic toxicityXx_NEWLINE_xXFor patients with solid tumors without known bone marrow involvement:\r\n* Peripheral absolute neutrophil count (ANC) >= 1000/mm^3\r\n* Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)\r\n* Hemoglobin >= 8.0 g/dL at baseline (may receive red blood cell [RBC] transfusions)Xx_NEWLINE_xXPatients with known bone marrow metastatic disease will be eligible for study provided they meet the blood counts (may receive platelet or packed [p]RBC transfusions provided they are not known to be refractory to red cell or platelet transfusions); these patients will not be evaluable for hematologic toxicityXx_NEWLINE_xXPatients with known bone marrow metastatic disease will be eligible for study provided they meet the blood counts in above criteria (may receive transfusions provided they are not known to be refractory to red cell or platelet transfusions); these patients will not be evaluable for hematologic toxicityXx_NEWLINE_xXPatients with known bone marrow metastatic disease will be eligible for study provided they meet the blood counts (may receive transfusions provided they are not known to be refractory to red cell or platelet transfusions); these patients will not be evaluable for hematologic toxicityXx_NEWLINE_xXPatients with known bone marrow metastatic disease will be eligible for study provided they meet the blood counts (may receive transfusions provided they are not known to be refractory to red cell or platelet transfusions); these patients will not be evaluable for hematologic toxicityXx_NEWLINE_xXPatients with known bone marrow metastatic disease will be eligible for study provided they meet the blood counts (may receive transfusions provided they are not known to be refractory to red cell or platelet transfusions); these patients will not be evaluable for hematologic toxicityXx_NEWLINE_xXHemoglobin (Hgb) greater than 8.0 g/dL (may have packed red blood cell [PRBC] transfusion)Xx_NEWLINE_xXMeasured within 28 days prior to registration: hemoglobin >= 10.0 g/dL with no blood transfusions (packed red blood cells in the past 28 days is permitted)Xx_NEWLINE_xXWhole blood transfusions in the last 120 days prior to entry to the study (packed red blood cells and platelet transfusions are acceptable)Xx_NEWLINE_xXHemoglobin > 8 g/dL (prior red blood cell [RBC] transfusion allowed); patients may be transfused to achieve this valueXx_NEWLINE_xXHemoglobin >= 8.0 g/dL (may receive red blood cell [RBC] transfusions)Xx_NEWLINE_xXINCLUSION CRITERIA FOR SECOND-LINE THERAPY: Patients may have a transfusion of red blood cells to meet the hemoglobin requirementXx_NEWLINE_xXINCLUSION CRITERIA FOR THIRD-LINE THERAPY: Patients may have a transfusion of red blood cells to meet the hemoglobin requirementXx_NEWLINE_xXHemoglobin levels at the time of or within 7 days prior to transfusions must have been ? 9.0 g/dL for the transfusions to qualify as required for the purpose of providing evidence of transfusion-dependent anemia.Xx_NEWLINE_xXPatients with bone marrow metastatic disease who do not meet the above criteria will be eligible to enroll in the study with the following count criteria; these patients will not be evaluable for hematologic toxicity or hematologic dose limiting toxicity (DLT)\r\n* ANC > 750/uL within 7 days prior to first dose of abemaciclib\r\n* Platelet count > 50,000/uL (may receive platelet transfusions) within 7 days prior to first dose of abemaciclib\r\n* Hemoglobin >= 7.5 g/dL (may receive red blood cells [RBC] transfusions) within 7 days prior to first dose of abemaciclibXx_NEWLINE_xXHemoglobin (Hgb) >= 10 g/dL (may be achieved with erythropoietin agents; no blood transfusions in the 28 days prior to entry)Xx_NEWLINE_xXBlood (packed red blood cells, platelets) transfusions within 1 month prior to study startXx_NEWLINE_xXPlatelet count >= 75,000/uL (platelet transfusions allowed provided the patient is not known to be refractory to red cell or platelet transfusions) for subjects with bone marrow involvement; these subjects will not be evaluable for hematologic toxicity or hematologic DLT, but will be subject to dose modifications based on hematologic criteriaXx_NEWLINE_xXHemoglobin < 9 g/dL (< 5.5 mmol/L; previous red blood cell [RBC] transfusion is permitted).Xx_NEWLINE_xXRed Blood cell transfusion dependent (defined as ? 2 RBC units required in the 8 weeks prior to starting in the study).Xx_NEWLINE_xXHemoglobin >= 8 g/dL (80 g/L) within 14 days prior cycle 1, day 1 (subjects may be receiving red blood cell [RBC] transfusions in accordance with institutional guidelines)Xx_NEWLINE_xXUnable to accept blood product transfusionsXx_NEWLINE_xXPlatelet count >= 75 x 10^9/L; subjects may receive red blood cells (RBC) transfusions or platelet transfusions, if clinically indicated in accordance with institutional guidelines; however, screening platelet count should be independent of platelet transfusions for at least 2 weeksXx_NEWLINE_xXPts may receive RBC or platelet transfusions, if clinically indicated, in accordance with institutional guidelinesXx_NEWLINE_xXHemoglobin >= 9.0 gm/dL (may receive RBC transfusions)Xx_NEWLINE_xXUse of red blood cell or platelet transfusions within 4 weeks of treatmentXx_NEWLINE_xXHave a hemoglobin ?9.0 g/dL without red blood cell transfusion for ?1 month.Xx_NEWLINE_xXHemoglobin >= 8 g/dL\r\n* Note: Patients may receive erythrocyte transfusions to achieve this hemoglobin level at the discretion of the investigator; initial treatment must not begin earlierXx_NEWLINE_xXAdequate Bone Marrow Function defined as peripheral absolute neutrophil count (ANC) >=1000/ microlitre (µL), platelet count >= 75,000/µL (transfusion independent, defined as not receiving platelet transfusions within a 7 day period prior to enrollment); and hemoglobin >= 8.0 grams (g)/decilitre (dL), may receive red blood cell (RBC) transfusions. Subjects with bone marrow involvement will be eligible for study (provided they meet the criteria) but will not be evaluable for hematologic toxicity.Xx_NEWLINE_xXHemoglobin >= 8.0 g/dL at baseline (may receive red blood cell [RBC] transfusions)Xx_NEWLINE_xXPatients with known bone marrow metastatic disease will be eligible for study provided they meet the blood counts above (may receive transfusions provided they are not known to be refractory to red cell or platelet transfusions); these patients will not be evaluable for hematologic toxicity; at least 5 of every cohort of 6 patients must be evaluable for hematologic toxicity for the dose-escalation part of the study; if dose-limiting hematologic toxicity is observed, all subsequent patients enrolled must be evaluable for hematologic toxicityXx_NEWLINE_xXHemoglobin >= 8.0 g/dL at baseline (may receive red blood cell [RBC] transfusions)Xx_NEWLINE_xXPatients with known bone marrow metastatic disease will be eligible for study provided they meet the blood counts specified above (may receive transfusions provided they are not known to be refractory to red cell or platelet transfusions); these patients will not be evaluable for hematologic toxicity; at least 5 of every cohort of 6 patients must be evaluable for hematologic toxicity for the dose-escalation part of the study; if dose-limiting hematologic toxicity is observed, all subsequent patients enrolled must be evaluable for hematologic toxicity.Xx_NEWLINE_xXHemoglobin >8.0 mg/dL without red blood cell transfusion ? 3 days prior to C1D1Xx_NEWLINE_xXHemoglobin >= 8.0 g/dL (may receive transfusions)Xx_NEWLINE_xXHemoglobin >= 9.0 g/dL (with or without red blood cell [RBC] transfusion)Xx_NEWLINE_xXHemoglobin ?8 g/dL, with no red blood cell (RBC) transfusions within the prior 14 days.Xx_NEWLINE_xXHemoglobin < 9 g/dL (< 5.5 mmol/L; previous red blood cell transfusion is permitted)Xx_NEWLINE_xXWithin 14 days prior to registration: Hemoglobin >= 10 g/dL; patients may be transfused packed red blood cells (PRBCs) up to 1 week prior to when enrollment labs are drawn; on study, transfusions may be given as clinically indicatedXx_NEWLINE_xXHemoglobin >= 10 g/dL (not requiring red blood cell [RBC] transfusions)Xx_NEWLINE_xXPrior Red blood cell (RBC) transfusion < 3 months prior to starting CC-90002.Xx_NEWLINE_xXHemoglobin >= 8 g/dl (may receive transfusions)Xx_NEWLINE_xXINCLUSION CRITERIA FOR STRATUM C: Hemoglobin >= 8 g/dl (may receive transfusions)Xx_NEWLINE_xXHemoglobin < 9 g/dL at the screening visit; (NOTE: subject may not have received any growth factors or blood transfusions within seven days of the hematologic laboratory values obtained at the screening visit)Xx_NEWLINE_xXHemoglobin 8.0 g/dL (may receive red blood cell [RBC] transfusions)Xx_NEWLINE_xXPatients must have symptomatic anemia untransfused with hemoglobin =< 9.5 g/dL within 8 weeks of registration or with red blood cell (RBC) transfusion-dependence (i.e., >= 2 units/month) confirmed for a minimum of 8 weeks before randomizationXx_NEWLINE_xXSubjects should not have packed red blood cells (PRBC) or platelet transfusion within 14 days of the screeningXx_NEWLINE_xXHemoglobin >= 8 g/dL (transfusions are permissible)Xx_NEWLINE_xXHemoglobin: >= 8.0 gm/dl (may transfuse peripheral red blood cells [PRBCs])Xx_NEWLINE_xXHas received blood transfusions or growth factors within the last 4 weeks prior to randomizationXx_NEWLINE_xXHemoglobin < 9 g/dL (< 5.5 mmol/L; previous red blood cell [RBC] transfusion is permitted)Xx_NEWLINE_xXPatients who have had a whole blood transfusion within 120 days prior to enrollment. (Packed red blood cells and platelet transfusions are acceptable)Xx_NEWLINE_xXHemoglobin ?9.0 g/dL (must be >2 weeks post-red blood cell transfusion)Xx_NEWLINE_xXHemoglobin >= 9 g/dL (transfusions allowed)Xx_NEWLINE_xXHemoglobin ? 8.0 g/dl (red blood cell (RBC) transfusions are permitted)Xx_NEWLINE_xXHemoglobin >= 9 g/dL, with no blood transfusions in the 28 days prior to study entryXx_NEWLINE_xXPacked red blood cell transfusions or erythropoietin therapy within 14 days prior to the study enrollment unless erythropoietin therapy has been used to maintain a stable condition for at least 1 month prior to the enrollmentXx_NEWLINE_xXWhole blood transfusions in the last 120 days prior to entry to the studyXx_NEWLINE_xXHematologic function, as follows (no red blood cell or platelet transfusions are allowed within 14 days of the first dose of enfortumab vedotin):Xx_NEWLINE_xXPatients with known bone marrow metastatic disease will be eligible for study provided they meet the blood counts (may receive transfusions provided they are not known to be refractory to red cell or platelet transfusions); these patients will not be evaluable for hematologic toxicityXx_NEWLINE_xXWithin two weeks prior to enrollment: Hemoglobin >= 9 gm/dL and > 7 days since last red blood cell transfusionXx_NEWLINE_xXWithin two weeks prior to enrollment: Not refractory to red cell or platelet transfusionsXx_NEWLINE_xXHemoglobin >= 9.0 g/dL (may receive packed red blood cell [prbc] transfusion)Xx_NEWLINE_xXTo be performed within 14 days prior to day 1 of protocol therapy: platelets >= 100,000/mm^3\r\n* NOTE: transfusion of blood products are not allowed to normalize baseline blood parameters, however subsequent transfusions are allowed per standard supportive care guidelinesXx_NEWLINE_xXTo be performed within 14 days prior to day 1 of protocol therapy: hemoglobin (HgB) >= 9.0 g/dL\r\n* NOTE: transfusion of blood products are not allowed to normalize baseline blood parameters, however subsequent transfusions are allowed per standard supportive care guidelinesXx_NEWLINE_xXNOTE: patients may not have received any growth factors or blood transfusions within seven days of the hematologic laboratory values obtained at the screening visitXx_NEWLINE_xXWithin 3 days before the first dose of study drug: hemoglobin > 8 g/dL (prior red blood cell [RBC] transfusion allowed); patients may be transfused to achieve this value; elevated indirect bilirubin due to post-transfusion hemolysis is allowedXx_NEWLINE_xXPatients should not be known to be refractory to red blood cell or platelet transfusionsXx_NEWLINE_xXPatients must be transfusion independent (i.e., no blood product transfusions for a period of at least 14 days prior to screening)Xx_NEWLINE_xXHemoglobin ? 8 g/dL (red blood cell [RBC] transfusion is allowed)Xx_NEWLINE_xXHemoglobin >= 9 g/dL (transfusions permitted)Xx_NEWLINE_xXHemoglobin >= 8.0 g/dl (red blood cell [RBC] transfusions are permitted) must be met during screening (within 21 days) and also prior to study drug administration on cycle 1 day 1Xx_NEWLINE_xXHemoglobin (Hb) at least 8.0 grams per deciliter (g/dL) at baseline (blood transfusions are allowed during the screening period to correct Hb values less than 8.0 g/dL).Xx_NEWLINE_xXHemoglobin (Hgb) >= 9 g/dL with or without packed red blood cells (pRBC) transfusionXx_NEWLINE_xXHemoglobin (Hb) at least 9 g/dL (or 5.69 mmol/L) at baseline (blood transfusions, hematopoietic growth factors and hematinics are not allowed during the 7 days prior to screening to correct Hb values less than 9 g/dL)Xx_NEWLINE_xXHemoglobin >= 8 g/dL; RBC transfusions and use of G-CSF will be allowed in order to meet eligibility parameters (unless dysfunction is secondary to lymphoma involvement)Xx_NEWLINE_xXSubjects must be transfusion independent (i.e., no blood product transfusions for a period of at least 14 days prior to screening).Xx_NEWLINE_xXHemoglobin >= 8 g/dL without red blood cell transfusions within 2 weeks of the initiation of treatmentXx_NEWLINE_xXUncontrolled autoimmune disorders. Patients with autoimmune disorders under control on medication may be included. Patients with pure red cell aplasia may be included if hemoglobin levels are relatively stable on transfusions or medicationXx_NEWLINE_xXAT SCREENING: Hemoglobin within institutional normal limits. Administration of growth factors or blood transfusions will not be allowed to confirm eligibility.Xx_NEWLINE_xXAT SCREENING: Platelet count within institutional normal limits. Administration of growth factors or blood transfusions will not be allowed to confirm eligibility.Xx_NEWLINE_xXPatients may be transfused with packed red blood cells (PRBCs) up to 7 days prior to when enrollment labs are drawn to achieve Hgb >= 9.0 mg/dLXx_NEWLINE_xXHemoglobin >= 8.0g/dl (may receive red blood cell [RBC] transfusions)Xx_NEWLINE_xXHemoglobin ? 8.0 g/dL (may receive transfusions)Xx_NEWLINE_xXWhole blood transfusions in the last 120 days prior to entry to the study (packed red blood cells and platelet transfusions are acceptable)Xx_NEWLINE_xXPatients known to be refractory to platelet or packed red cell transfusions per Institutional Guidelines, or a patient who refuses blood product support.Xx_NEWLINE_xXSubjects who are not willing to receive red blood cell (RBC) transfusions to treat low hemoglobin levelsXx_NEWLINE_xXHemoglobin >= 10.0 gm/dL (may receive red blood cell count [RBC] transfusions)Xx_NEWLINE_xXHemoglobin ? 9 g/dL (transfusions are allowed)Xx_NEWLINE_xXPlatelet transfusion and packed red blood cell transfusion can also be given prior to the start of treatment and treatment to achieve a target plt >= 75,000/uL and hemoglobin of >= 8.5 g/dl, provided that patients have not received growth factors for at least 14 days prior to entering trialXx_NEWLINE_xXHemoglobin >= 8 g/dL performed within 10 days of treatment initiation (red blood cell [RBC] transfusions are OK)Xx_NEWLINE_xXRBC transfusion-dependent anemia defined as: anemia requiring RBC transfusions of at least 1 unit of RBC every 6 weeks for hemoglobin =< 9.0 g/dLXx_NEWLINE_xXHemoglobin >= 10 g/dL (not requiring red blood cell [RBC] transfusions)Xx_NEWLINE_xXBlood transfusion (including blood products) within 1 week of screening.Xx_NEWLINE_xXPART 2 GROUP 1 INCLUSION CRITERIA: Hemoglobin (Hgb) >= 8 g/dL (may receive red blood cell [RBC] transfusion)Xx_NEWLINE_xXPatients must be willing to accept blood product transfusionsXx_NEWLINE_xXUROTHELIAL CARCINOMA EXPANSION COHORT: Hemoglobin >= 10 g/dL in the absence of packed red blood cells transfusion 28 days prior to dosing OR > 9 g/dL, if the value is constant across 2 readings within 2 weeks in the absence of packed red blood cells transfusion 28 days prior to dosingXx_NEWLINE_xXWhole blood transfusions in the last 120 daysXx_NEWLINE_xXAnemia or red blood cell (RBC)-transfusion dependence defined as follows: a) Anemia: defined for the purpose of this protocol as 1) a hemoglobin level < 10 g/L on every determination over 84 days before study-entry, without RBC-transfusions, or 2) a hemoglobin level < 10 g/L on a patient that is receiving RBC-transfusions periodically but not meeting criteria for transfusion-dependent patient as defined below; the baseline hemoglobin value for these subjects is the lowest hemoglobin level during the antecedent 84 days; b) RBC-transfusion-dependence: RBC-transfusion-frequency of >= 2 units packet red blood cell (PRBC)/28 days averaged over 84 days immediately pre-study-entry; there must not be any consecutive 42 days without an RBC-transfusion during this intervalXx_NEWLINE_xXTransfusion independent (no red blood cell or platelet transfusions in the preceding 2 weeks of screening)Xx_NEWLINE_xXHemoglobin >= 9 g/dl (no blood transfusions within 4 weeks prior to enrollment)Xx_NEWLINE_xXhemoglobin ? 9.0 g/dL (transfusions permissible)Xx_NEWLINE_xXPatients must be willing to receive transfusions of blood productsXx_NEWLINE_xXHemoglobin >= 8.0 mg/dL without red blood cell transfusion =< 7 days prior to C1D1Xx_NEWLINE_xXCAPMATINIB INCLUSION CRITERIA: Hemoglobin >= 9 g/dL (transfusions are allowed)Xx_NEWLINE_xXCERITINIB INCLUSION CRITERIA: Hemoglobin >= 8 g/dL (transfusions are allowed)Xx_NEWLINE_xXENTRECTINIB INCLUSION CRITERIA: Hemoglobin >= 8 g/dL (transfusions are allowed)Xx_NEWLINE_xXHemoglobin >= 8 g/dL without red blood cell transfusions within 2 weeks of the initiation of treatmentXx_NEWLINE_xXPHASE I: No blood transfusions 28 days prior to study entryXx_NEWLINE_xXPHASE II: No blood transfusions 28 days prior to study entryXx_NEWLINE_xXHemoglobin > 8g/dL (may receive transfusions).Xx_NEWLINE_xXPatients with known bone marrow metastatic disease will be eligible for study provided they meet the blood counts (may receive transfusions provided they are not known to be refractory to red cell or platelet transfusions); these patients will not be evaluable for hematologic toxicityXx_NEWLINE_xXPatients refractory to red blood cell or platelet transfusionsXx_NEWLINE_xXHemoglobin >= 9.0 g/dL and no blood transfusions in the 28 days prior to enrollmentXx_NEWLINE_xXPHASE I STUDY ELIGIBILITY CRITERIA:\r\nHemoglobin (Hgb) >= 10 g/dL in the absence of packed red blood cell transfusion 28 days prior to dosing OR Hgb 9-9.9 g/dL and the value is constant across 2 readings within 2 weeks, in the absence of packed red blood cell transfusion 28 days prior to dosingXx_NEWLINE_xXPHASE II COLORECTAL CANCER COHORT 6 (MEDI+C ONLY):\r\nHemoglobin (Hgb) >= 9 g/dL in the absence of packed red blood cell transfusion 28 days prior to dosingXx_NEWLINE_xXHb ? 9 g/dL (independent of transfusions or erythropoiesis-stimulating agents [ESA]).Xx_NEWLINE_xXPatients with solid tumors metastatic to bone marrow will be eligible for study but not evaluable for hematologic toxicity; these patients must not be known to be refractory to red cell or platelet transfusions; at least 2 of every cohort of 3 patients must be evaluable for hematologic toxicity; if dose limiting hematologic toxicity is observed at any dose level, all subsequent patients enrolled must be evaluable for hematologic toxicityXx_NEWLINE_xXSubjects with known bone marrow metastatic disease will be eligible for study provided they meet the specified blood counts (may receive transfusions provided they are not known to be refractory to red cell or platelet transfusions); these subjects will not be evaluable for hematologic toxicity; if dose-limiting hematologic toxicity is observed, all subsequent subjects enrolled must be evaluable for hematologic toxicityXx_NEWLINE_xXHemoglobin >= 9 g/dL (packed red blood cell [pRBC] transfusion +/- erythropoiesis-stimulating agents [ESA] are allowed) (must be within 7 days of MLA)Xx_NEWLINE_xXHemoglobin > 8 gm/dL, patients may be transfused with red blood cells (RBC’s)Xx_NEWLINE_xXPatients who refuse to receive blood transfusionsXx_NEWLINE_xXHemoglobin ? 8.0 g/dL (may receive RBC transfusions) Patients known to have bone marrow involvement with neuroblastoma are eligible provided that minimum ANC and platelet count criteria are met but are not evaluable for hematological toxicity.Xx_NEWLINE_xXHgb < 10.0 g/dL (unless the hemoglobin value has been stable, the subject is cardiovascularly stable, asymptomatic and judged able to withstand the RFA procedure) Note: If clinically indicated, subjects may receive platelets or packed red blood cell (RBC) transfusions and be re-evaluated after condition is treated.Xx_NEWLINE_xXHemoglobin >= 8 g/dL (80 g/L) (subjects may be receiving red blood cell [RBC] transfusions in accordance with institutional guidelines)Xx_NEWLINE_xXHemoglobin >= 8 g/dL (80 g/L) within 14 days prior to starting therapy (subjects may be receiving red blood cell [RBC] transfusions in accordance with institutional guidelines)Xx_NEWLINE_xXRelapsed/refractory MCL: Patients must be willing to receive transfusions of blood productsXx_NEWLINE_xXNewly diagnosed MCL: Patients must be willing to receive transfusions of blood productsXx_NEWLINE_xXANC >= 500 X 10^9 /L with transfusions allowed if stem cells availableXx_NEWLINE_xXHemoglobin >= 8.0 g/dL with transfusions allowed if stem cells available; patients with stem cells available are excluded if they require two platelet transfusions per week to maintain the minimum required platelet count; a bone marrow examination is not medically indicated for patients diagnosed with metastatic pheochromocytomaXx_NEWLINE_xXPatients may receive red blood cell (RBC) or platelet transfusions, if clinically indicated, in accordance with institutional guidelinesXx_NEWLINE_xXAnemic patient OR red blood cell (RBC)-transfusion-dependent patientXx_NEWLINE_xXAdequate hematocrit independent of red cell transfusionsXx_NEWLINE_xXHemoglobin >= 8 g/dL (packed red blood cell [PRBC] transfusions permitted)Xx_NEWLINE_xXHemoglobin >= 8 g/dl (may receive transfusions)Xx_NEWLINE_xXHemoglobin (Hgb) greater than 8.0 g/dL (may have packed red blood cell [PRBC] transfusion)Xx_NEWLINE_xXPlatelet count should be > 50,000/ul and hemoglobin should be > 8 gm/dl; patients may receive platelet or red blood cell transfusions to maintain hemoglobin and platelets at clinical appropriate levelsXx_NEWLINE_xXHemoglobin (Hgb) ? 9 g/dL. NOTE: subject must not have received any growth factor or blood transfusions within 14 days prior to the hematology values obtained at screening. Subjects requiring transfusions to meet eligibility criteria are not eligible.Xx_NEWLINE_xXHemoglobin at least 8.0 grams per deciliter (g/dL) at Baseline (blood transfusions are allowed during the screening period to correct hemoglobin values less than 8.0 g/dL) As blood transfusions are permitted to meet the hemoglobin criteria, participants requiring transfusion must not be known to be refractory to red blood cell or platelet transfusions.Xx_NEWLINE_xXHemoglobin (>=) 7.5 gram per deciliter (g/dL) ([>=] 5 millimole per liter [mmol/L]; prior red blood cell [RBC] transfusion is permitted)Xx_NEWLINE_xXWilling to undergo blood transfusions as deemed clinically necessary.Xx_NEWLINE_xXHemoglobin >= 8 g/dL; subjects may receive red blood cell transfusions as clinically indicated per institutional guidelines but screening hemoglobin should be independent of red blood cell transfusion for at least 3 days prior to cycle 1 day 1Xx_NEWLINE_xXPatients who have received no less than 20 transfusions of RBCs;Xx_NEWLINE_xXWhole blood transfusions in the last 120 days prior to entry to the study (packed red blood cells and platelet transfusions are acceptable).Xx_NEWLINE_xXWhole blood transfusions in the last 120 days prior to entry to the study (packed red blood cells and platelet transfusions are acceptable)Xx_NEWLINE_xXPart 1: hemoglobin level of ? 8 g/dL within 2 weeks of enrollment\r\n* Packed red blood cell (PRBC) transfusions will be allowed to patients with hemoglobin < 8g/dlXx_NEWLINE_xXAdequate bone marrow function defined as:\t\r\n* Subjects with known bone marrow metastatic disease will be eligible for study provided they meet the blood counts (may receive transfusions provided they are not known to be refractory to red cell or platelet transfusions); these subjects will not be evaluable for hematologic toxicity; at least 5 of every cohort of 6 patients must be evaluable for hematologic toxicity for the dose-escalation part of the study; if dose-limiting hematologic toxicity is observed, all subsequent subjects enrolled must be evaluable for hematologic toxicityXx_NEWLINE_xXPatients must be willing to receive transfusions of blood products.Xx_NEWLINE_xXPatients with known bone marrow metastatic disease will be eligible for study provided they meet the blood counts (may receive transfusions provided they are not known to be refractory to red cell or platelet transfusions); these patients will not be evaluable for hematologic toxicityXx_NEWLINE_xXHemoglobin >= 8 g/dL (may receive transfusions)Xx_NEWLINE_xXHemoglobin >= 10 g/dL (transfuse as necessary to raise levels, no transfusions within 7 days of start)Xx_NEWLINE_xXHemoglobin >= 8 g/dL; red blood cell transfusions are permitted to meet eligibility criteriaXx_NEWLINE_xXHemoglobin >= 8.0 g/dL (may receive red blood cell [RBC] transfusions)Xx_NEWLINE_xXHemoglobin >= 8.0 g/dL (may receive red blood cell [RBC] transfusions)Xx_NEWLINE_xXWhole blood transfusions in the last 120 days prior to entry to the study (packed red blood cells and platelet transfusions are acceptable)Xx_NEWLINE_xXHemoglobin >= 8 g/dL (packed red blood cells [PRBC] transfusions permitted)Xx_NEWLINE_xXHemoglobin >= 9 g/dL, unsupported by transfusionsXx_NEWLINE_xXTransfusion dependency defined by transfusion of at least 4 units of RBC (red blood cells) within 8 weeks before Screening; pre-transfusion Hgb (hemoglobin) values must be ? 9 g/dL to be taken into account.Xx_NEWLINE_xXHemoglobin >= 9 g/dL, without ongoing chronic blood transfusion or colony stimulating factor support to maintain normal levels; principal investigator approval is required; (limited red blood cell [RBC] transfusion is allowed for an acute change in hemoglobin)Xx_NEWLINE_xXHemoglobin greater than 8 g/dl (patients may receive transfusions to meet this parameter)Xx_NEWLINE_xXHemoglobin greater than 8 g/dL (may have received red blood cell [RBC] transfusions allowed)Xx_NEWLINE_xXHemoglobin (Hb) at least 8 g/dL at baseline (blood transfusions are allowed during the screening period to correct Hb values less than 8 g/dL)Xx_NEWLINE_xXFor patients with solid tumors without bone marrow involvement: hemoglobin >= 8.0 gm/dL (may receive red blood cell [RBC] transfusions)Xx_NEWLINE_xXPatients with known bone marrow metastatic disease will be eligible for study provided they meet the blood counts (may receive transfusions provided they are not known to be refractory to red cell or platelet transfusions); these patients will not be evaluable for hematologic toxicity; at least 5 of every cohort of 6 patients with a solid tumor must be evaluable for hematologic toxicity, for the dose-escalation part of the study; if dose-limiting hematologic toxicity is observed, all subsequent patients enrolled must be evaluable for hematologic toxicityXx_NEWLINE_xXFor patients with solid tumors without known bone marrow involvement: hemoglobin >= 8.0 g/dL (may receive red blood cell [RBC] transfusions)Xx_NEWLINE_xXPatients on Part B of the study with known bone marrow metastatic disease will be eligible for the study provided they meet the blood counts (may receive transfusions provided they are not known to be refractory to red cell or platelet transfusions); these patients will not be evaluable for hematologic toxicityXx_NEWLINE_xXHemoglobin >= 8 g/dl (may be after transfusion of packed red blood cells or use of erythropoiesis stimulating agents)Xx_NEWLINE_xXHemoglobin >= 10.0 g/dL (may receive red blood cell [RBC] transfusions)Xx_NEWLINE_xXHemoglobin ? 8 g/dL (80 g/L) within 14 days prior to randomization (subjects may be\n             receiving red blood cell [RBC] transfusions in accordance with institutional\n             guidelines)Xx_NEWLINE_xXAbsence of a regular red blood cell transfusion requirementXx_NEWLINE_xXPatients with known bone marrow metastatic disease will be eligible for study provided they meet the blood counts (may receive transfusions provided they are not known to be refractory to red cell or platelet transfusions); these patients will not be evaluable for hematologic toxicity; if dose-limiting hematologic toxicity is observed, all subsequent patients enrolled must be evaluable for hematologic toxicityXx_NEWLINE_xXHemoglobin >= 8.0 gm/dL (may receive packed red blood cell [PRBC] transfusions)Xx_NEWLINE_xXPatients on Part A1 or Part C of the study:\r\n* For patients with solid tumors or ALCL without bone marrow involvement:\r\n** Peripheral absolute neutrophil count (ANC) >= 1,000/mm^3\r\n** Platelet count >= 75,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions within a 7 day period prior to enrollment)\r\n** Hemoglobin >= 8.0 g/dL (may receive red blood cell [RBC] transfusions)\r\n* Patients with known bone marrow metastatic disease: \r\n** Peripheral absolute neutrophil count (ANC) >= 750/mm^3\r\n** Platelet count >= 25,000/mm^3 (may receive platelet transfusions)\r\n** Hemoglobin >= 8.0 g/dL (may receive RBC transfusions)\r\n** Not known to be refractory to RBC or platelet transfusions\r\nTransfusions are permitted to meet both the platelet and hemoglobin criteria; Note: patients with known bone marrow metastatic disease are not evaluable for hematological toxicity for the purposes of dose escalationXx_NEWLINE_xXPatients eligible for Part A2, Part A3, or Part B of the study must meet the hematologic criteria below for enrollment:\r\n* Peripheral absolute neutrophil count (ANC) >= 750/mm^3\r\n* Platelet count >= 25,000/mm^3 (may receive platelet transfusions)\r\n* Hemoglobin >= 8.0 g/dL (may receive RBC transfusions)\r\n* Not known to be refractory to red cell or platelet transfusions\r\nTransfusions are permitted to meet both the platelet and hemoglobin criteriaXx_NEWLINE_xXPatients must not have received a transfusion (platelets or red blood cells) within 4 weeks of the first dose of study treatment.Xx_NEWLINE_xXHemoglobin >= 9 g/dL\r\n* Blood transfusions are allowed at any time during the screening, treatment or follow-up period, according to the center recommendationsXx_NEWLINE_xXHemoglobin >= 90 g/L\r\n* Blood transfusions are allowed at any time during the screening, treatment or follow-up period, according to the center recommendationsXx_NEWLINE_xXAnemia that requires red blood cell transfusionsXx_NEWLINE_xXMust have symptomatic anemia untransfused with hemoglobin < 9.5 g/dL =< 8 weeks prior to randomization or with red blood cells (RBC) transfusion dependence (i.e., >= 2 units/month) confirmed for =< 8 weeks before randomization\r\n* NOTE: For non-transfusion dependent patients (i.e., receiving < 2 units/4 weeks x 8 weeks pre-study) who receive periodic transfusions, the mean 8 week pre-transfusion hemoglobin should be used to determine protocol eligibility and response reference\r\n* For non-transfusion dependent patients, a minimum of 2 pre-transfusion or un-transfused hemoglobin values are requiredXx_NEWLINE_xXHemoglobin >= 9 g/dL (prior to transfusions)Xx_NEWLINE_xXPatients in CRi must have evidence of hematologic recovery after prior therapy independent of red blood cell transfusionsXx_NEWLINE_xXHemoglobin ? 9 g/dL. Patients may receive red blood cells (RBC) and/or erythropoietin (EPO) and/or platelet transfusions in accordance with institutional guidelines.Xx_NEWLINE_xXRed blood cell (RBC) transfusion dependent, 1) Received at least 4 units of RBCs over any 8 consecutive weeks during the 16 weeks prior to randomization, 2) Pretransfusion Hb must have been less than or equal to (<=)9.0 gram per deciliter (g/dL)Xx_NEWLINE_xXPlatelet or packed red blood cell transfusion within 14 days of pre-treatment evaluationXx_NEWLINE_xXPatients who have received hematopoietic growth factor support within 14 days of day 1 of ibrutinib; patients who are Jehovah’s witnesses may be given an erythropoiesis-stimulating agent before and during the trial in lieu of red blood cell transfusions but anemia and/or red blood cell (RBC) transfusion dependence cannot be used for response assessment in these patientsXx_NEWLINE_xXHemoglobin (Hgb) >= 9.0 g/dL (no red blood cell [RBC] transfusion within past 14 days)Xx_NEWLINE_xXblood transfusions prior to 1990,Xx_NEWLINE_xXHemoglobin >= 9 g/dL (transfusions are acceptable)Xx_NEWLINE_xXHemoglobin ?8 g/dL and no red blood cell (RBC) transfusions during the prior 14 daysXx_NEWLINE_xXRed blood cell (RBC) transfusion dependent, defined as requiring at least 4 RBC units transfused over an 8-week period during the 16 weeks prior to Study Entry; pre-transfusion hemoglobin (Hb) should be less than or equal to 9.0 gram per deciliter (g/dL) to count towards the 4 units totalXx_NEWLINE_xXOne of the following diagnoses:\r\n* MDS with International Prognostic Scoring System (IPSS) score of INT-1 or higher and one of the following:\r\n** Symptomatic anemia with either hemoglobin < 10.0 g/dL or requiring red blood cell (RBC) transfusion\r\n** Thrombocytopenia with a history of two or more platelet counts < 50,000/uL or a significant hemorrhage requiring platelet transfusions\r\n** Neutropenia with two or more absolute neutrophil count (ANC) < 1,000/uL\r\n* Non-M3 AMLXx_NEWLINE_xXWithin 72 hour (h) of initiating study treatment: Hemoglobin (Hgb) >= 9.0 g/dL; Note: transfusions of blood and blood products as well as growth factor support are prohibited within 14 days prior to the first dose of study treatmentXx_NEWLINE_xXPatients must be willing to receive transfusions of blood productsXx_NEWLINE_xXHemoglobin >= 8 g/dL (may receive transfusions)Xx_NEWLINE_xXHemoglobin ? 8.0 g/dL (Use of erythropoietic stimulating factors and red blood cell [RBC] transfusion per institutional guidelines is allowed, however the most recent RBC transfusion may not have been done within 7 days prior to obtaining screening hemoglobin.)Xx_NEWLINE_xXHemoglobin >= 9 g/dL (transfusions allowed)Xx_NEWLINE_xXHemoglobin >= 8.0 g/dl (may receive red blood cell [RBC] transfusions)Xx_NEWLINE_xXHemoglobin (Hgb) >= 9 g/dL and no red blood cell (RBC) transfusion within the past 14 days prior to study registrationXx_NEWLINE_xXHemoglobin >= 9.0 g/dL (not requiring transfusions within the past 2 weeks)Xx_NEWLINE_xXHemoglobin >= 8 g/dL\r\n* Transfusions and erythropoietin supplementation permittedXx_NEWLINE_xXHemoglobin value >= 9 g/dL (Note: patients whose anemia has been corrected to a hemoglobin value >= 9 g/dL with blood transfusions are allowed)Xx_NEWLINE_xXHemoglobin > 9 g/dL (80 g/L) within 30 days prior to cycle 1 day 1 (subjects may be receiving red blood cell transfusions in accordance with institutional guidelines)Xx_NEWLINE_xXPatients should not have received any platelet transfusions in the last 4 weeks before screening dateXx_NEWLINE_xXHemoglobin value >= 9 g/dL (Note: patients whose anemia has been corrected to a hemoglobin value >= 9 g/dL with blood transfusions are allowed)Xx_NEWLINE_xXHemoglobin < 8g/dL (<4.9 mmol/L; prior red blood cell [RBC] transfusion is permitted)Xx_NEWLINE_xXSubjects must be willing to accept/continue transfusions to treat low hemoglobin levelsXx_NEWLINE_xXHemoglobin >= 8 g/dL (80 g/L) within 14 days prior to initial treatment (subjects may be receiving red blood cell [RBC] transfusions in accordance with institutional guidelines)Xx_NEWLINE_xXWhole blood transfusions in the last 120 days prior to entry to the study (packed red blood cells and platelet transfusions are acceptable.Xx_NEWLINE_xXHemoglobin >= 8 g/dL, unless if cytopenias are deemed to be due disease at discretion of clinical investigator; transfusions and growth factors are permissibleXx_NEWLINE_xXAdministration of growth factors or blood transfusions will not be allowed within 4 weeks of the hematology labs required to confirm eligibilityXx_NEWLINE_xXHemoglobin > 9 g/dL (80 g/L) within 7 days of time of consent (subjects may be receiving red blood cell transfusions in accordance with institutional guidelines)Xx_NEWLINE_xXHemoglobin >= 9 (packed red blood cells [pRBC] transfusion +/- erythropoiesis-stimulating agents [ESA] are allowed) (must be within 7 days of MLA)Xx_NEWLINE_xXHemoglobin > 8gm/dL (transfusions permitted)Xx_NEWLINE_xXPatients with lymphoma metastatic to bone marrow who have granulocytopenia, anemia, and/or thrombocytopenia will be eligible for study but not evaluable for hematologic toxicity (in Part A, there will be a maximum of one per cohort); such patients must meet the blood counts as in Part A (may receive transfusions provided they are not known to be refractory to red cell or platelet transfusions); if dose-limiting hematologic toxicity is observed, all subsequent patients enrolled in Part A must be evaluable for hematologic toxicityXx_NEWLINE_xXHematocrit =< 28% or hemoglobin =< 9 g/dL (but may have red blood cell [RBC] transfusion)Xx_NEWLINE_xXPatients must be willing to receive transfusions of blood productsXx_NEWLINE_xXHemoglobin < 5.6 mmol/L (9 g/dL) at the screening visit (note: patients may not have received any growth factors within 7 days or blood transfusions within 28 days of the hematologic laboratory values obtained at the screening visit)Xx_NEWLINE_xXHemoglobin >= 8 g/dL (may have received packed red blood cell transfusion)Xx_NEWLINE_xXHemoglobin >= 9.0 g/dL not requiring transfusions within the past 2 weeksXx_NEWLINE_xXHemoglobin >= 8.0 g/dL (may receive red blood cell [RBC] transfusions)Xx_NEWLINE_xXWithin 14 days after subjects signed the treatment consent: Hemoglobin >= 10 g/dl; patients may be transfused packed red blood cells (PRBCs) up to 1 week prior to when enrollment labs are drawn; on study, transfusions may be given as clinically indicatedXx_NEWLINE_xXAbsence of gross blood in stool; red blood on toilet paper only acceptable.Xx_NEWLINE_xXUnwilling to accept blood product transfusionsXx_NEWLINE_xXHemoglobin (Hb) at least 9 g/dL (or 5.69 mmol/L) at baseline (blood transfusions, hematopoietic growth factors and hematinics are not allowed during the 7 days prior to screening to correct Hb values less than 9 g/dL)Xx_NEWLINE_xXHemoglobin >= 9 g/dl (may transfuse packed red blood cells [PRBC] to meet parameter)Xx_NEWLINE_xXHemoglobin >= 9 g/dL; subjects may not have had a red blood cell (RBC) transfusion within 7 days of screening assessmentXx_NEWLINE_xXWithin 8 weeks of randomization: Hemoglobin value >= 9 g/dL (Note: patients whose anemia has been corrected to a hemoglobin value >= 9 g/dL with blood transfusions are allowed)Xx_NEWLINE_xXHemoglobin >= 9.0 mg/dL without red blood cell transfusion =< 7 days prior to cycle 1 day 1 of therapyXx_NEWLINE_xXRequirement for platelet transfusions.Xx_NEWLINE_xXHistory of 15 to 75 PRBC transfusionsXx_NEWLINE_xXMore than 6 months of cumulative iron-chelation therapy (such as daily deferasirox (Exjade) or deferiprone or 5x/week deferosamine). intermittent deferoxamine doses in association with blood transfusions are not exclusionary regardless of duration of such treatment. -- More than 3 years since patient began receiving regular transfusions (2 units per 8 weeks or 4 units received in a 3 month period).Xx_NEWLINE_xXPatients refractory to red blood cell or platelet transfusionsXx_NEWLINE_xXHematopoietic growth factors, transfusions of blood or blood products within 1 weekXx_NEWLINE_xXBlood transfusions or hemopoietic factor therapyXx_NEWLINE_xXHematopoietic growth factors, transfusions of blood or blood products within 1 weekXx_NEWLINE_xXPlatelet or red cell transfusions to help patients meet eligibility criteria are not allowed within 3 days before study enrollmentXx_NEWLINE_xXParticipants requiring blood transfusions to maintain hemoglobin (Hgb) eligibilityXx_NEWLINE_xXPacked red blood cell or platelet transfusion within 7 days of screening laboratory tests.Xx_NEWLINE_xXPatients who are platelet or red blood cell transfusion-dependent are eligibleXx_NEWLINE_xXPatients must be willing to receive transfusions of blood productsXx_NEWLINE_xXTREATMENT: Hemoglobin greater than 8 g/dl (patients may receive transfusions to meet this parameter)Xx_NEWLINE_xXHemoglobin >= 9 g/dL unsupported by transfusions within 7 daysXx_NEWLINE_xXRECURRENT/ PROGRESSIVE DIPG (STRATUM 1): Hemoglobin >= 8 g/dl (may receive transfusions)Xx_NEWLINE_xXRECURRENT/ PROGRESSIVE DIPG (STRATUM 1): Patients are known to be refractory to red blood cell or platelet transfusionsXx_NEWLINE_xXNON-PROGRESSED DIPG (STRATUM 2): Hemoglobin >= 8 g/dl (may receive transfusions)Xx_NEWLINE_xXNON-PROGRESSED DIPG (STRATUM 2): Patients are known to be refractory to red blood cell or platelet transfusionsXx_NEWLINE_xXHemoglobin >= 8 g/dL (transfusions are permissible)Xx_NEWLINE_xXHemoglobin >= 9 g/dl without packed red blood cell dependency, unless due to bone marrow involvement with lymphomaXx_NEWLINE_xXTransfusion dependent at baseline, defined as ? 4 U red blood cell (RBC) transfusion in the 8 weeks prior to first dose of MMBXx_NEWLINE_xXHemoglobin >= 8.0 g/dL (may receive red blood cell [RBC] transfusions)Xx_NEWLINE_xXHemoglobin ? 9.0 g/dL and not requiring > 1 unit red blood cell transfusion per month; subjects receiving therapeutic erythropoietin preparations in accordance with the FDA product label are eligible to enroll;Xx_NEWLINE_xXHistory of transfusions < 10 RBC units and must not be RBC transfusion dependentXx_NEWLINE_xXPatients with leukemia must not be known to be refractory to red blood cell or platelet transfusions.Xx_NEWLINE_xXHemoglobin ? 9 g/dL (with no RBC transfusions within 7 days of Screening)Xx_NEWLINE_xXHemoglobin < 9 g/dL (< 5.5 mmol/L; previous red blood cell transfusion is permitted)Xx_NEWLINE_xXHemoglobin >= 8.0 g/dL (may receive transfusions)Xx_NEWLINE_xXHemoglobin >= 5.59 mmol/L or 9 g/dL; up to 5% deviation is tolerated; transfusions and growth factors are allowedXx_NEWLINE_xXHemoglobin >= 8.0 g/dL (may receive red blood cell [RBC] transfusions)Xx_NEWLINE_xXAny patient requiring chronic maintenance of red blood cell, white blood cell or granulocyte counts through the use of blood transfusions or growth factor support (e.g. Neulasta®, Neupogen®)Xx_NEWLINE_xXHemoglobin >= 9.0 g/dL (not requiring transfusions within the past 2 weeks)Xx_NEWLINE_xXHemoglobin (Hb) >= 9g/dL (women) or >= 11g/dL (men) (supportive transfusions will be allowed during induction and maintenance phases to maintain these levels)Xx_NEWLINE_xXHemoglobin >= 8 g/dL (with transfusions)Xx_NEWLINE_xXAdequate renal, hepatic, and bone marrow function without frequent blood product or hematopoietic growth factor support (eg use of erythropoietin or transfusions > 2 units packed red blood cells every 3 months)Xx_NEWLINE_xXHemoglobin > 9.0 g/dL (patients are allowed to receive transfused red blood cells [RBC] to achieve this level)Xx_NEWLINE_xXHemoglobin >= 8 g/dL (80 g/L) within 14 days prior to randomization (subjects may be receiving red blood cell [RBC] transfusions in accordance with institutional guidelines)Xx_NEWLINE_xXRed blood cell transfusion within 2 weeks prior to anticipated start of study treatment.Xx_NEWLINE_xXAnemia, Hemoglobin (Hgb) ? 9.0 g/dL or ? 2 units of Red Blood Cells (RBCs) within 84 daysXx_NEWLINE_xXNo platelet or blood transfusions within two weeks of obtaining baseline laboratory valuesXx_NEWLINE_xXNo blood modifiers while enrolled in the study (i.e., growth factors such as erythropoiesis-stimulating agent [ESA] or filgrastim [G-CSF]); NOTE: blood transfusions are allowed per institutional guidelinesXx_NEWLINE_xXHemoglobin ? 9 g/dL (transfusions are allowed)Xx_NEWLINE_xXPatients may receive RBC or platelet transfusions, if clinically indicated, in accordance with institutional guidelinesXx_NEWLINE_xXHemoglobin >= 9 g/dl (subjects may be receiving red blood cell [RBC] transfusions in accordance with institutional guidelines)Xx_NEWLINE_xXAdequate bone marrow function defined as absolute neutrophil count (ANC) >=1000/microliter, hemoglobin >=8.0 gram per deciliter (g/dL) (may receive red blood cell transfusions), platelets >=75,000/ microliter (transfusion independent, defined as not receiving platelet transfusions within a 7 day period prior to enrollment).Xx_NEWLINE_xXHemoglobin (Hb) > 8 gr/dL not supported by transfusionsXx_NEWLINE_xXMust have adequate organ function as defined by the following values: Adequate bone marrow function defined as-absolute neutrophil count (ANC) >=1000/ microliter (µL), hemoglobin >=8.0 grams (g)/ deciliter (dL) (may receive red blood cell transfusions), platelets >=75,000/µL (transfusion independent, defined as not receiving platelet transfusions within a 7 day period prior to enrollment).Xx_NEWLINE_xXHas received a transfusion (platelets or red blood cells) within 3 weeks before the first dose of niraparibXx_NEWLINE_xXHas received a transfusion (platelets or red blood cells) within 3 weeks of the first dose of niraparibXx_NEWLINE_xXHemoglobin ? 8.0 g/dL within 21 days prior to randomization. Use of erythropoietic stimulating factors and red blood cell (RBC) transfusions per institutional guidelines is allowed, however most recent RBC transfusion may not have been done within 7 days prior to obtaining screening hemoglobin.Xx_NEWLINE_xXHemoglobin (Hb) greater than or equal to 10g/dL at baseline (blood transfusions,hematopoietic growth factors and hematinics are allowed during the Prerandomization Phase to correct Hb values less than 10g/dL).Xx_NEWLINE_xXHemoglobin >= 9.0 g/dL not requiring transfusions within the past 2 weeksXx_NEWLINE_xXHemoglobin ? 8 g/dL without red blood cell transfusion within 72 hours of screening.Xx_NEWLINE_xXAdministration of growth factors or blood transfusions will not be allowed to confirm eligibilityXx_NEWLINE_xXHemoglobin greater than 8g/dl (patients may receive transfusions to meet this parameter)Xx_NEWLINE_xXBlood transfusions or hemopoietic factor therapyXx_NEWLINE_xXPatients must be willing to receive transfusions of blood productsXx_NEWLINE_xXPlatelets (PLT) >= 90 x 10^9/L without transfusionsXx_NEWLINE_xX6-MMP >= 12,000/8 x 10^8 red blood cell (RBC) within 21 days prior to enrollmentXx_NEWLINE_xXHemoglobin (Hgb) >= 8 g/dL and no red blood cell (RBC) transfusion within the past 21 days prior to study registrationXx_NEWLINE_xXAnemia (hemoglobin [Hgb] < 8.0 gm/dl) or leukopenia (absolute neutrophil count [ANC] < 1,000/mcL); use of red cell transfusions, erythropoietin, or filgrastim (G-CSF), as ordered by the managing oncology service, is acceptable and does not preclude participationXx_NEWLINE_xXReceived any red blood cell (RBC) transfusion within 28 days prior to randomization.Xx_NEWLINE_xXGENERAL INCLUSION CRITERIA FOR SUBPROTOCOLS: Patients with known bone marrow metastatic disease will be eligible for study provided they meet the blood counts (may receive transfusions provided they are not known to be refractory to red cell or platelet transfusions); these patients will not be evaluable for hematologic toxicityXx_NEWLINE_xXHemoglobin > 8.0 g/dL; red blood cell transfusions to help patients meet eligibility criteria are not allowed within 3 days before study enrollmentXx_NEWLINE_xXworsening hemoglobin should be ? 1.5 g/dL decrease from preinjectable HMA (HYPOMETHYLATING AGENT) baseline value in subjects not receiving RBC (RED BLOOD CELL) transfusionsXx_NEWLINE_xXmeaningful worsening in RBC (RED BLOOD CELL) or platelet transfusion requirement Definition of stable disease is based on modified IWG (INTERNATIONAL WORKING GROUP) 2006 criteria:Xx_NEWLINE_xXESAs (Erythropoiesis stimulating agent) and other RBC (Red blood cell) hematopoietic growth factors (eg, interleukin-3)Xx_NEWLINE_xXHemoglobin >= 9 g/dL (transfusions and/or erythropoietin are permitted)Xx_NEWLINE_xXHemoglobin ? 9.0 g/dL (in the absence of red blood cell transfusions in the prior 14 days)Xx_NEWLINE_xXHemoglobin >= 8.0 gm/dL (may receive packed red blood cell [pRBC] transfusions)Xx_NEWLINE_xXHemoglobin >= 9.0 g/dL (may receive red blood cell [RBC] transfusions)Xx_NEWLINE_xX